recombinant parathyroid hormone (1-84) (Natpara)
Jump to navigation
Jump to search
Indications
- hypoparathyroidism (FDA-approved Jan 2015)
- patients not responding to calcium supplementation & 1,25-dihydroxyvitamin D[2]
- osteoporosis
Dosage
- injection one a day
Adverse effects
(common)
- hypercalciuria, hypercalcemia, nausea
- osteosarcoma has been observed in rat studies[2]
Mechanism of action
- may reduce risk of vertebral fractures in women with osteoporosis
More general terms
Components
- thalidomide (Thalamid, Corronarobetin)
- melphalan (Alkeran, L-PAM, L-sarcolysin phenylalanine mustard, melphalan flufenamide, Pepaxto)
- prednisone (Deltasone, Orasone, Liquid Pred, Meticortin, Rayos)
References
- ↑ Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB; Treatment of Osteoporosis with Parathyroid Hormone Study Group. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007 Mar 6;146(5):326-39. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17339618
- ↑ 2.0 2.1 2.2 Reuters, Sept 12, 2014 U.S. FDA panel recommends approval of NPS hormone replacement drug. http://news.yahoo.com/u-fda-panel-recommends-approval-nps-hormone-replacement-214259435--finance.html
FDA News Release. January 23, 2015 FDA approves Natpara to control low blood calcium levels in patients with hypoparathyroidism. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm431358.htm